Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Buying vol up 72%,income 47m,book pps 1.31,cash 1.2,debt/eq .23 positive,eps up 200% this year,pps dropped from offering at market price,appears factored in now (we shall see)
Watch for thru .80 resistance,1m short has 8 days to cover but they might take profits here and just cover with max,with many news events coming,covering would be smart/safe here
Just hit #1 on my screener,time to load up for me,bids wouldn’t fill,I kept getting jumped,mm/someone wants lots of shares,my slap ave in is .7701
All green and blue candle today,over 1m short,demand growing,could see a squeeze soon
I liked this better when she was a runnin' ...
ACRX
AcelRX Pharmaceuticals Inc
1.24
-0.04 (-3.13%)
Volume: 56,275
Day Range: 1.20 - 1.29
Bid: 1.17
Ask: 1.26
Last Trade Time: 7:02:44 PM EDT
Total Trades: 413
ACRX
AcelRX Pharmaceuticals Inc
1.3401
0.1901 (16.53%)
Volume: 227,454
Day Range: 1.143 - 1.318
Last Trade Time: 7:20:53 PM EDT
Puts at zero,they might let this go again soon
Fda news Monday ish,fomo should start soon
What news,I don’t see any?
ACRX
AcelRX Pharmaceuticals Inc
1.10
-0.05 (-4.35%)
Volume: 90,041
Day Range: 1.01 - 1.19
Last Trade Time: 7:42:26 PM EDT
ACRX
AcelRX Pharmaceuticals Inc
1.10
-0.05 (-4.35%)
Volume: 90,041
Day Range: 1.01 - 1.19
Last Trade Time: 7:42:26 PM EDT
News out :
Item 8.01. Other Events.
As previously disclosed by AcelRx Pharmaceuticals, Inc. (the “Company”) in its filings with the U.S. Securities and Exchange Commission, the Company had received a letter from The Nasdaq Stock Market LLC ("Nasdaq") on April 26, 2023 notifying the Company of its non-compliance the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market.
On June 15, 2023, the Company received notice from Nasdaq confirming that the Company has cured its bid price deficiency and has regained compliance with the Minimum Bid Price Rule, and that this matter is now closed.
Last 5 days,bounced off sma50(10 min)volume daily increase with beginning/middle/eod surges,accumulation,p.r. coming,earth shattering product,awesome s.s,FITS ALL OF OUR RULES TO TRADE except 10% inside ownership (it’s.30)
Accumulation continues,pattern is unmistakable,low risk/high reward beauty swing
ZERO BORROW coming fast,Shares available to short just dropped 75%,only 2k remaining ,watch for demand,next leg coming
ACRX
AcelRX Pharmaceuticals Inc
1.07
0.12 (12.63%)
Volume: 478,488
Day Range: 0.9974 - 1.25
Last Trade Time: 7:57:35 PM EDT
71 day breakout,climbing scanners,should get found now,demand growing and bid humping started
Accumulation continues,17 days now,demand is 3mm stack 11k top @.85, good to see channel hold let go,it can go up or down now,no one selling with earth changing news coming
Shares available to short dropped 75% 110k covered ,still 740k short and shares running out,ZERO BORROW soon at this rate (tomorrow at latest rate)
They letting it go!! Looks all natural now
Sma 20,crossed above sma50,sma 200 @2.56, 200%run room from here
Accumulation continuing(14 days now)looks like pps going up also,.89 res . Watch for demand/bid humping
Today,1st daily macd breakout since jan.$2.78 run high, august $7+(over 20day run) July $7+, bulls have ran well every time here,I expect the pattern to continue
Many pr events expected soon,DOD government contracts started,big money coming makes this insanely undervalued
7m float,11m os,856k short(12%)institutions 12%,analysts target $4.00
https://stockcharts.com/h-sc/ui?s=acrx&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/acrx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100
https://www.barchart.com/stocks/quotes/acrx/opinion
ACRX
AcelRX Pharmaceuticals Inc
0.67
-0.005 (-0.74%)
Volume: 55,084
Day Range: 0.66 - 0.699799
Last Trade Time: 7:30:33 PM EDT
ACRX
AcelRX Pharmaceuticals Inc
0.698
-0.0079 (-1.12%)
Volume: 46,593
Day Range: 0.68 - 0.710593
Last Trade Time: 7:53:51 PM EDT
Well , THAT report was ugly ..
Shorts have NO reason to cover now ... sad .
Loading up .70 for events,30th ,I don’t want to miss out this time
Loading up .70 for events,30th ,I don’t want to miss out this time
ACRX
AcelRX Pharmaceuticals Inc
1.35
-0.09 (-6.25%)
Volume: 104,429
Day Range: 1.36 - 1.45
Last Trade Time: 4:59:18 PM EST
ACRX
AcelRX Pharmaceuticals Inc
2.08
-0.12 (-5.45%)
Volume: 108,679
Day Range: 2.04 - 2.24
Last Trade Time: 7:56:11 PM EST
ACRX
AcelRX Pharmaceuticals Inc
2.39
-0.02 (-0.83%)
Volume: 105,069
Day Range: 2.28 - 2.40
Last Trade Time: 4:00:02 PM EST
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
https://ih.advfn.com/stock-market/NASDAQ/acelrx-pharmaceuticals-ACRX/stock-news/89737073/acelrx-pharmaceuticals-announces-european-peer-rev
I know , let's have a stock split .....
When should we tell the shareholders ?
How does 15 minutes sound ? ( After the market has closed ) .
Is that reasonable ?
Who cares ? They were suckers for staying with us this long anyway .
ACRX
AcelRX Pharmaceuticals Inc
0.201
-0.001 (-0.50%)
Volume: 706,429
Day Range: 0.1951 - 0.218699
Bid: 0.1667
Ask: 0.2552
Last Trade Time: 6:17:52 PM EDT
Total Trades: 1,514
ACRX Detailed Quote
ACRX
AcelRX Pharmaceuticals Inc
0.2802
-0.0068 (-2.37%)
Volume: 793,318
Day Range: 0.2711 - 0.30
Bid: 0.29
Ask: 0.3039
Last Trade Time: 5:44:31 PM EDT
Total Trades: 814
ACRX Detailed Quote
results.
"Our commercial emphasis on procedural suites has resulted in a successful quarter of growth for DSUVIA, while also reducing our costs, allowing us to focus on our robust pipeline," stated Vince Angotti, Chief Executive Officer of AcelRx. "DSUVIA continues to demonstrate solid sales growth in the procedural suite setting, with adoption beginning across national accounts. Our European partner, Aguettant, also is gearing up for the launch of DZUVEO. This said, we remain mindful of our operating costs and plan to continue reducing our cash burn. Importantly, we remain in discussions with potential partners with the commercial resources to amplify the expected growth for DSUVIA."
Mr. Angotti continued, "We're focused on a potential Emergency Use Authorization for our lead nafamostat candidate, Niyad™, in 2023 as we are making solid progress across the supply chain. Additionally, our pre-filled syringes remain on track for NDA submissions this year. We believe each of these product candidates will provide multiple value-creating catalysts in the near-term."
ACRX
AcelRX Pharmaceuticals Inc
0.23
-0.0124 (-5.12%)
Volume: 1,132,603
Day Range: 0.222 - 0.2424
Bid: 0.2294
Ask: 0.23
Last Trade Time: 7:45:31 PM EDT
Total Trades: 1,999
ACRX Detailed Quote
AcelRX Pharmaceutica (ACRX)
0.24 ? -0.0029 (-1.19%)
Volume: 2,287,790 @06/03/22 7:58:49 PM EDT
Bid Ask Day's Range
0.2 0.2405 0.2245 - 0.267
ACRX Detailed Quote
Watch this one. Conference today, about to be selling in Europe. This is going to be a money making pig. Pay attention
Followers
|
94
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1412
|
Created
|
02/13/11
|
Type
|
Free
|
Moderators |
Market Cap: $108 Million
Cash: $72 Million
Price: $2.40
Shares Out: 45.3 Million
Upcoming Major Milestones
Zalviso Phase 3 Results in July 2017
DSUVIA PDUFA Date October 12, 2017
Zalsviso NDA Resubmission in Q4 2017
DSUVIA CHMP Opinion in 1H 2018 (EU Approval )
Presentation June 2017
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjczNjExfENoaWxkSUQ9MzgxNTY1fFR5cGU9MQ==&t=1
Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target
https://finance.yahoo.com/news/jefferies-sees-strong-upside-acelrx-145225845.html
Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)...
https://insiderfinancial.com/biotech-catalyst-play-acelrx-pharmaceuticals-inc-nasdaqacrx
While Zalviso is our near-term catalyst, the DSUVIA decision probably holds more weight from a valuation perspective. Why? Because peak sales for this one are estimated at a little over $1.1 billion in the US alone. If FDA gives a green light for commercialization to the asset, therefore, the company could have a blockbuster drug on its hands. Combine that with the close to $400 million in revenues potential from Zalviso, and AcelRx could very justifiably become a multibillion-dollar biotech company before the end of the decade.
https://finviz.com/quote.ashx?t=acrx&ty=c&ta=1&p=d
Shs Outstand | 119.10M |
Shs Float | 116.83M |
Short Float | 13.47% |
Insider Own | 2.00% |
Inst Own | 34.80% |
Inst Trans | 43.60% |
Inst Trans | 43.60% |
ROE | 66.50% |
ROI | 120.80% |
Employees | 54 |
Forward P/E | 16.13 |
Recom | 1.70 |
52W Range | 1.01 - 2.94 |
minor resistance $1.70 [-chart]finviz.com/chart.ashx?t=acrx&ty=c&ta=1&p=d&s=l[/chart]
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |